The previous study on NAFLD and NASH patients reported increased VAP-1 concentration in fibrosis stage F ≥ 2 in comparison to F0/F1, whereas our study shows a stronger correlation with progressive fibrosis. Here, AOC3 is linked to metabolic dysfunction-associated steatotic liver disease.